This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biogen Idec Building 26 In Research Triangle Park. (Photo: Business Wire)

Biogen Idec (NASDAQ: BIIB) today dedicated a new facility in Research Triangle Park (RTP), consolidating its 300-person Patient Services operation with the existing RTP campus. The new 190,000 square foot building is anticipated to achieve LEED-Gold certified status in the coming months and will accommodate increasing levels of manufacturing activity at the site. The official groundbreaking for the building was in April of 2011.

Biogen Idec Building 26 in Research Triangle Park. (Photo: Business Wire)

Biogen Idec Building 26 in Research Triangle Park. (Photo: Business Wire)

“With the opening of this beautiful facility Biogen Idec has united on one site more than 1,000 people dedicated to meeting the needs of patients with serious diseases,” said George A. Scangos, Ph.D. and chief executive officer, for Biogen Idec. “The expansion of our footprint in RTP underscores our commitment to providing a secure supply of medicines and to helping patients overcome obstacles to receiving them.”

As the “front door” to the Biogen Idec campus in North Carolina, the five-story Building 26 will initially house 500 employees.

“Our RTP site focuses on patient care – from manufacturing high quality therapies to providing patient support and financial assistance. With this new building, our employees are constantly reminded of our purpose through the patient stories that adorn the main areas and workspaces within the building,” said Machelle Sanders, vice president, Manufacturing and general manager, for Biogen Idec RTP.

“North Carolina is a leader in biotech and Biogen Idec is an important part of that success,” said Gov. Bev Perdue. “This new facility will further strengthen the company’s manufacturing and Patient Services operations, in addition to helping ensure its continued success in North Carolina.”

As the second largest independent biotech company in North Carolina and ninth largest employer in RTP, Biogen employs more than 1,000 people in the state. Onsite, Biogen Idec manufactures commercial products AVONEX ® (interferon beta-1a) and TYSABRI ® (natalizumab), both indicated for multiple sclerosis (MS), plus a growing number of other clinical products. The Patient Services group, which serves MS patients and their caregivers, has its inbound/outbound call center in Building 26. The group handles approximately 950,000 calls annually and processed more than $300 million in financial assistance for patients last year.

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company, and patients worldwide benefit from its leading multiple sclerosis therapies. For more information, please visit www.biogenidec.com.

Biogen Idec Safe Harbor

This press release contains forward-looking statements, which speak only as of the date of this press release. Actual results may differ materially from our expectations due to the risks and uncertainties described in Biogen Idec’s periodic reports filed with the Securities and Exchange Commission.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs